Neosoma Brain Mets
K252922Neosoma, Inc. · cleared 2025-12-17 · product code QIH · Radiology
Premarket evidence — what FDA accepted
source quote (p.6)
“Neosoma Brain Mets is a Software as a Medical Device (SaMD) that is designed specifically for the semi-automatic segmentation of previously diagnosed brain metastases.”
source quote (p.4)
“The Neosoma software uses an artificial intelligence algorithm (i.e., deep learning neural networks) to contour (segment) known or previously diagnosed brain tumors on MRI images for qualified and trained medical professionals.”
Validation studies (1)
Retrospective clinical
n=70 patients
endpoints: Sensitivity rate, to assess the true positive rate of lesion identification; False Positive Rate, to assess the number of false positive lesions per MRI; DSC (Dice Similarity Coefficient), to assess the degree of overlap between device output and the reference standard.; 95th percentile Hausdorff Distance (HD95) for true-positive lesions, to assess the maximum boundary distance between the device segmentation and the reference standard.; Mean Surface Distance (MSD) for true-positive lesions, to assess the average distance between device and reference standard surfaces.
standards: IEC 62304:2006/AC:2015
Reported performance (2 observations)
source quote (p.12)
“0.90 with 95% CI of 0.87 0.94”
source quote (p.13)
“0.86 with 95% CI of 0.83 0.89”
Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.
Predicate network
Postmarket — what happened after clearance
- predicate_cohort_contagion
K252922 shares predicate K203235 with K252304 (syngo.via RT Image Suite VC10), whose product code MUJ recorded 35 recall event(s) in the trailing 24 months.
first seen 2026-07-08 · predicate:K203235 sibling:K252304
Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.
Reimbursement — how devices like this got paid
Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).